Enliven Therapeutics, Inc.
ELVN
$19.80
$0.110.56%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 75.14% | 73.85% | 58.23% | 3.94% | 79.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.51% | 17.95% | 30.63% | 50.37% | 110.85% |
| Operating Income | -25.51% | -17.95% | -30.63% | -50.37% | -110.85% |
| Income Before Tax | -19.67% | -11.49% | -17.92% | -54.43% | -102.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.67% | -11.49% | -19.31% | -54.43% | -102.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.67% | -11.49% | -19.31% | -54.43% | -102.83% |
| EBIT | -25.51% | -17.95% | -30.63% | -50.37% | -110.85% |
| EBITDA | -25.60% | -18.01% | -30.73% | -50.50% | -111.42% |
| EPS Basic | 1.30% | 5.24% | -1.67% | 32.00% | 83.80% |
| Normalized Basic EPS | -9.80% | -1.08% | -8.92% | 35.88% | 84.89% |
| EPS Diluted | 1.30% | 5.24% | -1.67% | 32.00% | 83.80% |
| Normalized Diluted EPS | -9.80% | -1.08% | -8.92% | 35.88% | 84.89% |
| Average Basic Shares Outstanding | 21.23% | 17.64% | 17.37% | 127.09% | 1,152.45% |
| Average Diluted Shares Outstanding | 21.23% | 17.64% | 17.37% | 127.09% | 1,152.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |